ClinConnect ClinConnect Logo
Search / Trial NCT06520176

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Launched by THE AFFILIATED PEOPLE'S HOSPITAL OF NINGBO UNIVERSITY · Jul 20, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Multiple Myeloma Etoposide Cytarabine Peg Rh G Csf Hematopoietic Stem Cell Mobilization

ClinConnect Summary

This clinical trial is looking at two different treatment plans to help collect blood stem cells from patients with newly diagnosed multiple myeloma, a type of blood cancer. The trial compares a combination of three medications (etoposide, cytarabine, and Pegfilgrastim) known as the EAP regimen, with another treatment plan that includes cyclophosphamide and G-CSF, referred to as the GC regimen. The goal is to find out which approach is more effective and safe for helping patients gather the stem cells they need for a procedure called autologous stem cell transplantation (ASCT).

To participate in this trial, patients need to be newly diagnosed with multiple myeloma and have a good performance status, meaning they can carry out daily activities with minimal issues. They must also have a life expectancy of at least three months and be able to understand the study and provide consent. Participants will receive either the EAP or GC treatment and will be monitored for how well the treatments work and any side effects. This study is currently recruiting patients, and it aims to enroll a total of 99 individuals. This is an important opportunity to potentially benefit from new treatments that could improve outcomes for patients with this condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients newly diagnosed as multiple myeloma.
  • 2. Indication for ASCT.
  • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
  • 4. Life expectancy ≥ 3 months.
  • 5. Subjects must be able to understand the protocol and sign the informed consent.
  • Exclusion Criteria:
  • 1. Cardiac function class II or higher or cardiac ejection fraction \<40%.
  • 2. Serum direct bilirubin (DBIL)\>2× upper limit of normal (ULN).
  • 3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3× ULN.
  • 4. Serum creatinine clearance rate≤30%.
  • 5. Patients with active infection.
  • 6. Previously received hematopoietic stem cell mobilization.

About The Affiliated People's Hospital Of Ningbo University

The Affiliated People's Hospital of Ningbo University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations among healthcare professionals, researchers, and academic institutions. With a commitment to improving patient outcomes and contributing to the global medical community, the hospital prioritizes ethical standards and patient safety in all its clinical research endeavors. Through its robust infrastructure and expertise, the Affiliated People's Hospital of Ningbo University plays a pivotal role in enhancing the understanding and treatment of various health conditions.

Locations

Hangzhou, Zhejiang, China

Hangzhou, Zhejiang, China

Wenzhou, Zhejiang, China

Taizhou, Zhejiang, China

Lishui, Zhejiang, China

Wenzhou, , China

Shaoxing, Zhejiang, China

Huzhou, Zhejiang, China

Taizhou, Zhejiang, China

Jinhua, Zhejiang, China

Ningbo, Zhejiang, China

Jiaxing, Zhejiang, China

Ningbo, Zhejiang, China

Shaoxing, Zhejiang, China

Dongyang, Zhejiang, China

Jinhua, Zhejiang, China

Patients applied

0 patients applied

Trial Officials

Ying Lu

Principal Investigator

The Affiliated People's Hospital of Ningbo University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported